TR201909600T4 - Lipide edilmiş oksoadenin türevleri. - Google Patents

Lipide edilmiş oksoadenin türevleri. Download PDF

Info

Publication number
TR201909600T4
TR201909600T4 TR2019/09600T TR201909600T TR201909600T4 TR 201909600 T4 TR201909600 T4 TR 201909600T4 TR 2019/09600 T TR2019/09600 T TR 2019/09600T TR 201909600 T TR201909600 T TR 201909600T TR 201909600 T4 TR201909600 T4 TR 201909600T4
Authority
TR
Turkey
Prior art keywords
lipidated
oxoadene
derivatives
oxoadenins
oxoadenin
Prior art date
Application number
TR2019/09600T
Other languages
English (en)
Inventor
Johnson David
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of TR201909600T4 publication Critical patent/TR201909600T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bir fosfo- veya fosfonolipide kovalent şekilde bağlanmış, nitrojen heterosiklil ile ikame edilmiş oksoadenin molekülü içeren yeni lipide edilmiş oksoadeninlerin, interferon-a ve diğer immüno-uyarıcı sitokinlerin indükleyicileri olduğu gösterilir. Bileşikler, immüno-uyarıcılar ve adjuvanlar olarak faydalıdır.
TR2019/09600T 2009-08-07 2010-08-06 Lipide edilmiş oksoadenin türevleri. TR201909600T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23213209P 2009-08-07 2009-08-07

Publications (1)

Publication Number Publication Date
TR201909600T4 true TR201909600T4 (tr) 2019-07-22

Family

ID=43544685

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09600T TR201909600T4 (tr) 2009-08-07 2010-08-06 Lipide edilmiş oksoadenin türevleri.

Country Status (15)

Country Link
US (1) US9044481B2 (tr)
EP (2) EP2461690A4 (tr)
JP (1) JP5759992B2 (tr)
KR (1) KR20120055623A (tr)
CN (1) CN102469790B (tr)
AU (1) AU2010279299B2 (tr)
BR (1) BR112012002349A2 (tr)
CA (1) CA2768195A1 (tr)
EA (1) EA023536B1 (tr)
ES (1) ES2732999T3 (tr)
MX (1) MX2012001524A (tr)
SG (1) SG178237A1 (tr)
TR (1) TR201909600T4 (tr)
WO (1) WO2011017611A1 (tr)
ZA (1) ZA201200646B (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SI2320905T1 (sl) * 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
JP2011530562A (ja) * 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
SI2734186T1 (sl) 2011-07-22 2018-11-30 Glaxosmithkline Llc Sestavek
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
ES2653254T3 (es) 2012-08-24 2018-02-06 Glaxosmithkline Llc Compuestos de pirazolopirimidina
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
MX358025B (es) 2012-11-20 2018-08-02 Glaxosmithkline Llc Star Compuestos novedosos.
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
WO2015036044A1 (en) * 2013-09-13 2015-03-19 Telormedix Sa Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood
MX377916B (es) 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
KR102581546B1 (ko) 2015-03-06 2023-09-25 에프. 호프만-라 로슈 아게 벤즈아제핀 다이카복스아미드 화합물
WO2016142880A1 (en) * 2015-03-10 2016-09-15 Glaxosmithkline Biologicals Sa Compositions and uses
CN108055842B (zh) 2015-09-17 2021-06-29 豪夫迈·罗氏有限公司 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
ES2805724T3 (es) 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
US10774099B2 (en) 2015-12-14 2020-09-15 Glaxosmithkline Biologicals Sa Phospholipidation of imidazoquinolines and oxoadenines
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
EP3464274B1 (en) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
US20210371440A1 (en) 2018-04-13 2021-12-02 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
MX2020013785A (es) 2018-07-03 2021-03-25 Jiangsu Hengrui Medicine Co Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
MX2021014353A (es) 2019-05-23 2022-02-21 The Univ Of Montana Adyuvantes de vacunas basados en ligandos de receptores tlr.
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2022008286A (es) 2020-01-02 2022-08-08 Jiangsu Hengrui Medicine Co Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma.
KR102549083B1 (ko) 2021-02-01 2023-06-29 주식회사 에이티솔루션 레이다 전자 표적 발생 장치에서 발생되는 표적의 거리를 최소화하는 전파 지연 장치 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3042540B2 (ja) * 1990-08-20 2000-05-15 ミヨシ油脂株式会社 ８―ヒドロキシアデノシン―５′―リン酸を含むアデノシンモノホスフェート系三量体、その製造方法及びその化合物からなる蛋白質合成阻害剤
JPH093091A (ja) * 1995-06-21 1997-01-07 Rikagaku Kenkyusho ヌクレオシド誘導体物質、その製造法及び抗腫瘍剤
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP2038290B1 (en) * 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
EP2132209B8 (en) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2326646B1 (en) * 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
JP2011530562A (ja) * 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体

Also Published As

Publication number Publication date
KR20120055623A (ko) 2012-05-31
MX2012001524A (es) 2012-02-29
JP2013501730A (ja) 2013-01-17
US9044481B2 (en) 2015-06-02
EP3199159B1 (en) 2019-04-10
ES2732999T3 (es) 2019-11-27
CA2768195A1 (en) 2011-02-10
BR112012002349A2 (pt) 2015-10-13
AU2010279299B2 (en) 2015-10-01
US20120135963A1 (en) 2012-05-31
EP3199159A1 (en) 2017-08-02
EA023536B1 (ru) 2016-06-30
AU2010279299A1 (en) 2012-03-29
ZA201200646B (en) 2013-06-26
CN102469790B (zh) 2014-12-03
SG178237A1 (en) 2012-03-29
JP5759992B2 (ja) 2015-08-05
CN102469790A (zh) 2012-05-23
EP2461690A4 (en) 2013-03-27
EP2461690A1 (en) 2012-06-13
EA201290036A1 (ru) 2012-12-28
WO2011017611A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
TR201909600T4 (tr) Lipide edilmiş oksoadenin türevleri.
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1114764T1 (el) Παραγωγα προλινης ως αναστολεις καθεψινης
CY1116399T1 (el) Πυραζολυλαμινοπυριδινες ως αναστολεις της fak
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1118199T1 (el) Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk
PH12014502169A1 (en) N-cyclylamides as nematicides
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
SV2010003617A (es) Fungicidas
EA201591064A1 (ru) Новые производные пиридина
MX2010006565A (es) Derivados de benzimidazol sustituido por carboxilo o hidroxilo.
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CY1115863T1 (el) Ενωσεις τριαζολοπyριδινης
MX360330B (es) Regimen de administracion para nitrocatecoles.
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
MX349373B (es) Nuevos derivados de pirazina.
MY156525A (en) 2,5,7-substituted oxazolopyrimidine derivatives
TR201902057T4 (tr) Tetrasiklin bileşikleri.